Please provide your email address to receive an email when new articles are posted on . Sotatercept reduced risk for adverse outcomes in patients with advanced pulmonary arterial hypertension. The ...

Merck MRK announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending approval of an expanded indication for its ...

For recently diagnosed pulmonary arterial hypertension (PAH), adding sotatercept (Winrevair) to standard care lowered the risk of clinical worsening, the randomized HYPERION trial showed. Among 320 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in combination with other pulmonary ...

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...

EMA committee recommends approval of an expanded indication for Merck’s Winrevair in adults with pulmonary arterial hypertension: Rahway, New Jersey Monday, December 15, 2025, 1 ...

WASHINGTON -- The novel investigational therapy seralutinib effectively reduced pulmonary vascular resistance (PVR) in patients with pulmonary arterial hypertension (PAH) on standard background ...

The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...

Gossamer Bio advances the Feb. 2026 PROSERA Phase 3 readout for seralutinib in PAH, with expanded endpoints and a new ILD trial. Learn why GOSS stock is a hold.

Benefit with sotatercept seen among adults with pulmonary arterial hypertension diagnosed less than a year earlier. (HealthDay News) — The addition of sotatercept, an activin-signaling inhibitor, to ...

Sotatercept reduced the risk of major morbidity and mortality events by 76% in high-risk patients with PAH compared with placebo. The ZENITH trial was stopped early for efficacy. Adverse events were ...

Future Cardiol. 2013;9(3):335-349. The pivotal trial that established sildenafil as a treatment for WHO Group 1 PH was the SUPER trial. [102] SUPER enrolled WHO functional class II and III PAH ...